Effective Deal Making in Drug Delivery

Table of Contents

1. Introduction

2. Market Overview

• 2.1 Types of Drug Delivery
• 2.2 Development of the Drug Delivery Market
• 2.3 The Current and Evolving Market
• 2.4 Future Market Challenges
• 2.5 Drug Delivery Companies
  • 2.5.1 Principal Players in Drug Delivery
  • 2.5.2 The Changing Landscape: M&A Activity
  • 2.5.3 The True Scope of the Drug Delivery Sector

3. Key Drivers in Drug Delivery

• 3.1 Improving the Therapeutic Index
• 3.2 Patient Compliance
• 3.3 Patent Prolongation
• 3.4 Life Cycle Management

4. Commercialisation Strategies

• 4.1 Introduction
• 4.2 Returns to Innovation
• 4.3 Drug Delivery Product Offerings
• 4.4 Exploitation Strategies
• 4.5 Business Models
• 4.6 Product, Strategy and Business Models for Drug Delivery Technology
• 4.7 Applicability to Segments of the Pharmaceutical Product Life Cycle
• 4.8 Assessment of Attractiveness of Each Option
  • 4.8.1 Divestment to a Service-Based Company
  • 4.8.2 Licensing to Pharmaceutical Companies
  • 4.8.3 Sales of Devices
  • 4.8.4 Service Offering
  • 4.8.5 Development of Drugs in Collaboration with other Companies
  • 4.8.6 In-House Drug Development
• 4.9 Compatibility of Product Offerings
• 4.10 Conclusion

5. Alliances in Drug Delivery

• 5.1 Drug Delivery Deals Database
• 5.2 Drug Delivery Deal Activity
• 5.3 Financial Analysis of Drug Delivery Deals

6. Major Pharmaceutical Company Drug Delivery Deal Activity

• 6.1 Johnson & Johnson
• 6.2 Pfi zer
• 6.3 GlaxoSmithKline (GSK)
• 6.4 Novartis
• 6.5 Sanofi -aventis
• 6.6 Roche
• 6.7 AstraZeneca
• 6.8 Merck & Co
• 6.9 Abbott Laboratories
• 6.10 Wyeth

7. Valuation Methods

• 7.1 Integrated Benchmarking and ENPV Calculation
• 7.2 Other Methods
• 7.3 Benchmarking
  • 7.3.1 Feasibility Search
  • 7.3.2 Information Gathering and Analysis
  • 7.3.3 Approximate Valuation
  • 7.3.4 Refi nement of Valuation
• 7.4 Expected Net Present Value
• 7.5 Agreement Structure
  • 7.5.1 Value Sharing
  • 7.5.2 Risk Sharing
• 7.6 Valuation of Drug Delivery Systems
  • 7.6.1 Enabling Technology
  • 7.6.2 Enhancing Technology

8. Drug Delivery Alliance Development Process

• 8.1 Needs Identifi cation
  • 8.1.1 Driving Factors
    • 8.1.1.1 Market Drivers
    • 8.1.1.2 Technology Drivers
  • 8.1.2 Tools Needs Identifi cation
    • 8.1.2.1 Portfolio Analysis
    • 8.1.2.2 Value Chain Analysis
• 8.2 Identifying Opportunities and Partners
• 8.3 Development of Commercial Relationships

9. Drug Delivery Agreements

• Table of drug delivery agreements linked to the PharmaDeals® v2 Agreements Database

Tables

• 1. Typical maximum doses per administration
• 2. Marketed recombinant biopharmaceuticals among the top 200 selling prescription drugs
• 3. Publicly quoted specialty pharmaceutical companies that focus on drug delivery
• 4. Elan' s partnering activity
• 5. Major patent expirations, 2008 - 2012
• 6. Strategies for the exploitation of innovation
• 7. Business models
• 8. Generic strategies for commercialisation
• 9. Product offerings and target segments
• 10. Compatibility of product offerings
• 11. Number of drug delivery deals by therapeutic area, 1997 - October 2008
• 12. Number of drug delivery deals by product type, 1997 - October 2008
• 13. Average total deal values for drug delivery deals, 1997 - October 2008
• 14. Average upfront payments for drug delivery deals, 1997 - October 2008
• 15. Average milestone payments for drug delivery deals, 1997 - October 2008
• 16. Average equity investment payments for drug delivery deals, 1997 - October 2008
• 17. Top ten pharmaceutical companies by 2007 worldwide healthcare revenue
• 18. Johnson & Johnson drug delivery deals
• 19. Alza drug delivery deals (part of Johnson & Johnson)
• 20. Pfizer drug delivery deals
• 21. Pharmacia drug delivery deals
• 22. GlaxoSmithKline drug delivery deals
• 23. Novartis drug delivery deals
• 24. Sanofi-aventis drug delivery deals
• 25. Roche drug delivery deals
• 26. AstraZeneca drug delivery deals
• 27. Abbott drug delivery deals
• 28. Merck & Co. drug delivery deals
• 29. Wyeth drug delivery deals
• 30. Benchmarking methodology overview
• 31. Sources of information
• 32. Cumulative probabilities
• 33. Example ENPV calculation
• 34. Pharmaceutical industry event calendars
• 35. Key factors leading to successful alliances between companies
• 36. Drug delivery agreements linked to PharmaDeals

Figures

• 1. Pharmaceutical company R&D drug delivery projects by route of delivery
• 2. Drug delivery mergers and acquisitions, 1997 - 2008
• 3. Effect of controlled release formulations
• 4. Doses of chemotherapeutic agent required to achieve maximum effect
• 5. Estimated value in 2008 worldwide sales of the top 200 prescription drugs by year of US patent expiry
• 6. Life cycle management
• 7. All deal activity, 1997 - 2008
• 8. Drug delivery deal activity, 1997 - 2008
• 9. All deals according to deal type, 1997 - 2008
• 10. Drug delivery deals according to deal type, 1997 - 2008
• 11. Number of drug delivery deals by therapeutic area, 1997 - 2008
• 12. Number of drug delivery deals by product type, 1997 - 2008
• 13. Percentage of all deals with some financial information, 1997 - 2008
• 14. Percentage of drug delivery deals with some financial information, 1997 - 2008
• 15. Integrated valuation methods
• 16. Ideal benchmarking deal cluster
• 17. Example pharmaceutical deal force field
• 18. Attrition by therapeutic area
• 19. Success rates for life cycle management projects
• 20. Pharmaceutical product decision tree
• 21. Enhanced revenues due to drug delivery system
• 22. Enhancement of patent life
• 23. Drug delivery alliance development process